Abiopharma

🔍 FOLETTA MARK G (Director)

Company: DEXCOM INC (DXCM)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Sold 3,801 shares of Common Stock at $74.0991 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 53,051.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 199 shares of Common Stock at $74.8187 per share (Direct)
  Date: 2026-06-15 | Code: S | equity_swap_involved: 0 | shares_owned_after: 52,852.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-15 | Code: H | shares_owned_after: 6,331.00 | Footnotes: F5

Footnotes:

• F1: On March 13, 2026, The Foletta Family Trust DTD 1/30/2015 (the "Trust") adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by the Trust. The shares set forth above were sold pursuant to the 10b5-1 Plan.
• F2: This transaction was executed in multiple trades at prices ranging from $73.70 to $74.685. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
• F3: Shares are held by The Foletta Family Trust DTD 1/30/2015, with respect to which the Reporting Person is a trustee.
• F4: This transaction was executed in multiple trades at prices ranging from $74.78 to $75.55. The price above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
• F5: Represents unvested restricted stock units which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.